Press
12/27/2010 Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar ...more
11/01/2010 Vicus Therapeutics Receives $244,479 Grant for Qualifying Therapeutic Discovery Project to Develop VT-122 (etodolac, propranolol) for Patients with Advanced Cancer ...more
06/16/2010 Vicus Therapeutics Announces Positive Results of Phase 2 Trial of VT-122 for the treatment of Cachexia in Patients with Advanced Lung Cancer and presented at ASCO 2010 ...more
03/31/2009 Vicus Therapeutics Announces Acceptance of Abstract at ASCO 2010 for Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer ...more
04/01/2009 Vicus Therapeutics Announces Submission of Final Study Report for Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer ...more
04/21/2008 Vicus Therapeutics Announces Last Patient Out of Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer ...more
01/07/2007 Vicus Therapeutics Announces FDA Approval of Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer ...more
